Skip to content

Standardization research of external herbal medicine treatment on malignant pleural effusion

Standardization research of external herbal medicine treatment on malignant pleural effusion

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003580
Enrollment
Unknown
Registered
2013-09-08
Start date
2013-09-09
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant pleural effusion

Interventions

Herbal Group:Kangai Xiaoshui Ointment and symptomatic treatment

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with malignant tumor diagnosed by pathology or cytology; 2. Patients with pleural effusion diagnosed by B ultrasound or imageological examination; 3. Cancer cell can be found from pleural effusion or diagnosed pleural metastasis; 4. No history of intraperitoneal chemotherapy and/or intraperitoneal immunotherapy within 3 weeks; 5. No servere disfunction of heart, liver and kidney; 6. Aged 18 to 80 years; 7. Able to participate in study procedures and QoL evaluations; 8. Understand and agree to receive the treatment, and sign information consent form.

Exclusion criteria

Exclusion criteria: 1. Non-conformance of the entry criteria as above; 2. Patients with skin ulceration or servere hypersusceptibility; 3. Patients in process of radiotherapy/chemotherapy or within 1 month.

Design outcomes

Primary

MeasureTime frame
The quantity of pleural effusion evaluation;TCM Symptom Scale;

Secondary

MeasureTime frame
Drainage quantity of pleural effus/Body surface area;Quality of Life;

Countries

China

Contacts

Public ContactLiqun Jia

China-Japan Friendship Hospital

liqun-jia@hotmail.com+86 10 84205735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026